# Cedilla Therapeutics

Source: https://onco.cc/companies/cedilla-therapeutics/  
OnCo record `cedilla-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cedilla Therapeutics was a company that tried to make small-molecule drugs that change how stable cancer-driving proteins are. Its investor says it closed down in 2024.

## Summary

Cedilla Therapeutics launched in April 2018 with $56.2 million in Series A funding from Third Rock Ventures, to discover small molecules that exploit insights into protein stability and to apply them to proteins that drive cancer and other diseases, working upstream of native protein degradation pathways. Third Rock Ventures says the company wound down operations in 2024. No named drug candidate was found in the sources read.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Cedilla Therapeutics, Inc.
- HQ: Cambridge, MA
- Type: biotech

## Notes

- Company website (cedillatx.com) did not respond; the launch release reprinted by BioSpace and the Third Rock entry are the sources.
- Founding year not stated; 2018 is the launch and Third Rock investment year.
- No named programme or trial found.

## Sources

- Launch press release (BioSpace reprint): https://www.biospace.com/third-rock-ventures-launches-cedilla-therapeutics-with-56-million-investment-to-target-protein-stability-using-small-molecule-therapeutics
- Third Rock Ventures portfolio entry: https://www.thirdrockventures.com/portfolio/cedilla

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- companies: [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/)

---
JSON: https://onco.cc/api/v1/entities/cedilla-therapeutics.json